This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...
Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...
A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...
HERTFORDSHIRE, England, and PITTSBURGH, May 18, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the Wixela™ Inhub™ ...
Mylan N.V. MYL received a significant boost when the FDA approved its generic version of GlaxoSmithKline’s GSK Advair Diskus — Wixela Inhub — following a few setbacks. Notably, this is the first ...
LONDON (Alliance News) - Shares in Consort Medical PLC fell early Tuesday after the drug delivery company warned that delays to Mylan NV's Wixela inhaler for lung disease treatment will hit annual ...
HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela™ Inhub™ (fluticasone ...
DEAR PEOPLE’S PHARMACY: My father has severe COPD. The doctors at the Department of Veterans Affairs hospital prescribed Wixela, in addition to several other inhalers. Soon, he began to notice ...
(AP) -- The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan's version in three strengths ...
The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration today approved Mylan’s version in three strengths for ages 4 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results